跳至主要内容
临床试验/NCT01955512
NCT01955512已完成2 期

Effect of Clopidogrel on Allergen Challenge in Asthma

University of Southampton1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2013年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
24
试验地点
1
主要终点
Change in sputum eosinophils following allergen challenge in the presence and absence of clopiodgorel

研究概览

简要总结

In asthma, breathing in an allergen, such as house dust mite induces inflammation in the airways. This process appears to involve an interaction between two different sorts of blood cells, platelets and white blood cells via a receptor called the P2Y12 receptor. The purpose of this study is to determine whether the drug clopidogrel which blocks the P2Y12 receptor on platelets, reduces inflammation following breathing in house dust mite in people with mild asthma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of asthma
  • Step one of treatment by GINA (2006) guidelines
  • baseline FEV1 >80% predicted

排除标准

  • current smoker
  • ex smoker who quit <1 year prior to study and pack history >10 pack years
  • current use of aspirin or other anticoagulant medication
  • Diagnosis or documented history of bronchopulmonary aspergillosis or uncontrolled infections
  • Any clinically significant cardiopulmonary abnormalities not related to pre-existing asthma
  • Past or present tuberculosis, systemic lupus erythematosis or multiple sclerosis
  • Any clinically significant neurological, renal, endocrine, gastrointestinal, hepatic or haematological abnormalities uncontrolled with standard treatment
  • History of psychiatric, medical or surgical disorders that may interfere with study
  • Clinical history suggestive of respiratory infection in month preceding study
  • Alcohol or recreational drug abuse
  • Diagnosis of immunodeficiency requiring treatment
  • Treatment with immunomodulators (inhaled corticosteroids in two months or oral corticosteroids in six months prior to study)
  • Ongoing allergen desensitisation therapy
  • Regular use of sedatives, hypnotics, tranquillisers
  • Positive hepatitis viral antigens or antibodies
  • Blood donation within 3 months of the study
  • Live immunisation <4 wks prior to study
  • Inability to understand directions for study assessment
  • Inability to be contacted in case of emergency
  • Participation in another study at the same time or within a prior 3-month period

研究组 & 干预措施

Placebo

Placebo Comparator

Arm given placebo

干预措施: Placebo (Drug)

Clopidogrel

Experimental

Group given clopidogrel

干预措施: Clopidogrel (Drug)

结局指标

主要结局

Change in sputum eosinophils following allergen challenge in the presence and absence of clopiodgorel

时间窗: 8 days

次要结局

  • Provoking concentration of methacholine inducing 20% fall in forced expiratory volume in 1 second(8 days)
  • Change in sputum tissue factor inhibitor concentration following allergen challenge in the presence and absence of clopidogrel(8 days)
  • Change in sputum thrombin activatable finbrinolysis inhibitor concentration following allergen challenge in the presence and absence of clopidogrel(8 days)
  • Change in urine fibrin degradation products and leukotriene E4 following allergen challenge in the presence and absence of clopidogrel(8 days)
  • Change in sputum tissue factor concentration following allergen challenge in the presence and absence of clopidogrel(8 days)
  • Change in sputum P-selectin concentration following allergen challenge in the presence and absence of clopidogrel(8 days)
  • Change in peripheral blood eosinophil and platelet counts following allergen challenge in the presence and absence of clopidogrel(8 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验